Polycationic compounds and uses thereof
Aspects of the present invention relate to compounds and methods useful in modulating angiogenesis and methods of treating or preventing diseases associated with angiogenesis by administering a polycationic compound. The present invention relates to methods of use and compositions for inhibiting angiogenesis-mediated disorders in mammals including animals and humans. Additionally, this invention relates to the combined use of polycations with other anti-angiogenesis agents for the treatment of different angiogenesis-mediated disorders. Additionally, those polycationic compounds can be used with various anti-inflammatory and cytotoxic agents as well as with radio-therapeutic agents in cancer patients to prevent and treat tumor growth and metastasis.
1. A salicylamide compound of formula:
wherein:
n is 2 to 10;
R 1 is H or
R 2 is C 1 to C 9 straight or branched alkyl, where R 2 is optionally substituted with one or more —NH 2 , N(CH 3 ) 2 , or
R 3 is C 1 to C 9 straight or branched alkyl, where R 3 is optionally substituted with one or more —NH 2 , N(CH 3 ) 2 , or
and
R 4 is OH, NH 2 , or
wherein A is OH or NH 2 ;
or salt thereof.
2. The salicylamide compound of claim 1 wherein:
n is 2 to 10;
R 1 is H;
R 2 is C 1 to C 9 straight alkyl, where R 2 is optionally substituted with one or more —NH 2 , N(CH 3 ) 2 , or
R 3 is C 1 to C 9 straight alkyl; and
R 4 is OH, NH 2 , or
wherein A is OH or NH 2 ;
or salt thereof.
3. The salicylamide compound of claim 1 wherein:
n is 2 to 10;
R 1 is H;
R 2 is C 1 to C 9 straight alkyl, where R 2 is optionally substituted with one or more —NH 2 or N(CH 3 ) 2 ;
R 3 is C 1 to C 9 straight alkyl; and
R 4 is OH or NH 2 ;
or salt thereof.
4. The salicylamide compound of claim 1 wherein:
n is 2 to 10;
R 1 is H;
R 2 is C 1 to C 9 straight alkyl, where R 2 is optionally substituted with one or more —NH 2 ;
R 3 is C 1 to C 9 straight alkyl; and
R 4 is NH 2 ;
or salt thereof.
5. A pharmaceutical composition comprising the salicylamide compound of claim 1 and a pharmaceutically acceptable carrier.
6. A method of antagonizing heparin in a mammal comprising administering the compound of claim 1 to the mammal.
7. A method of antagonizing heparin in a mammal comprising administering the composition of claim 5 to the mammal.
8. A method of inhibiting anti-Factor Xa in a mammal comprising administering the compound of claim 1 to the mammal.
9. A method of inhibiting anti-Factor Xa in a mammal comprising administering the composition of claim 5 to the mammal.